Increasing the quality of life in NSCLC patients by Obdivo and Taxoter with hyperthermia

42^nd Euro Congress on Cancer Science & Therapy

June 08, 2022 | WEBINAR

S. Badzgaradze Kh. Shotadze

Medical Center of â??â??SAROVâ??â??, Georgia

Scientific Tracks Abstracts: J Cancer Sci Ther

Abstract :

Topicality: Treatment of oncological patients and getting clinical remission is an unfortunate topic even for the 21st century; despite the correctly selected therapy, which gives minimal risks of complications because of the chemo sensitive tests, there are important problems connected with the quality of life of patients and naturally we ask questions to ourselves: How could we manage to increase the quality of life in oncological patients on the 3rd and 4th levels and decrease the number of the side effects that accompany Ch/therapy and R/therapy procedures. Aim: The aim of the study was the patient with a 55-year diagnosis: NSCLC Thigh bone MTS, 3rd stage; R / therapy and 4 Courses CH /therapy; ECOG-2. Clinical remission was not achieved; Symptoms of progression of the hip fracture were strengthened, and the institution was addressed with the aforementioned history. Methods and Materials: For the patient was selected CH/courses with hyperthermia and target therapy, we use Docetaxel 80 mg / m2 and obdivo recommended to strengthen the course effectiveness, weaken toxicity and to improve the quality of life recommended for the treatment CH/therapy + target therapy with hyperthermia and hypoglycemia; For this procedure, a hyperthermic camera was installed, where the procedure is carried out at 43-48 degrees Celsius, and we have a sugar content of 25-30000 per one 40-45 mm / l in the bloodstream. Results: Only 2 courses were conducted with the patient with a CH/therapy and target therapy with hyperthermia. Conclusion: So, we managed to get maximal results through high-tech hyperthermic chemotherapy, patient’s clinical remission and this was without any side effects. Increasing the quality of life, We recommend giving a hyperthermic chemotherapy and target therapy in oncological patients at 3rd and 4th stage, which is a firm guarantee of increasing their quality of life.

Biography :

Sophie badzgaradze did her studies from 1992-1998 In institute of Critical Care Medicine at Tbilisi medical State University. In 2010 she completed her PhD at American University in Tbilisi. She did her training courses such as: The Basics of Homotoxicology in the Rheumatology and Gastroenterology, Symposium - "Modern Aspects of Bioregulation Medicine", Modern Clinical Medicine, Achievements and Latest Technologies, Scientific Practical Relations in Medicine - Reality and Perspectives, 34th Euro Global Summit on Cancer Therapy and Radiation oncology, 37 th Conference of the International Clinical Hyperthermia Society and many other courses.